Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
Safety and Effectiveness of Laparoscopic Sentinel Lymph Node Navigation Combined With Dual-endoscope Surgery for Early Stomach Cancer: a Prospective, Single-centre, Single-arm Clinical Study
研究概览
详细说明
Stomach cancer is one of the common malignant tumours worldwide, and in China, the incidence and mortality rates of stomach cancer remain high, posing a major public health burden. With the widespread implementation of stomach cancer screening in China, the detection rate of early-stage stomach cancer has significantly increased, now accounting for 19.5% of all stomach cancer cases. Early-stage stomach cancer (T1 stage) has a much better prognosis than advanced-stage cancer, with a 5-year survival rate exceeding 90% after standard treatment. Endoscopic submucosal dissection (ESD), due to its minimally invasive nature and ability to preserve stomach function, has become the standard treatment for certain cT1a-stage stomach cancers. However, for early-stage stomach cancer patients with a higher risk of lymph node metastasis, the lymph node metastasis rate can be close to 20%. In this context, if these patients only undergo endoscopic removal, they may face a higher risk of tumour residue. The traditional standard treatment is radical gastrectomy, usually combined with regional lymph node dissection (D1 or D2). Although this surgery is effective for cancer control, it can cause significant trauma, leading to irreversible changes to the patient's post-operative physiology and function, as well as long-term complications such as malnutrition, reflux oesophagitis and reduced quality of life, which have become key issues affecting the recovery of early-stage stomach cancer patients.
With the development of endoscopic technology (gastroscopy) and laparoscopic minimally invasive surgery, the concept of "function-preserving" surgery for early gastric cancer has been gaining increasing attention. This concept aims to minimise surgical trauma and preserve the anatomical structure and physiological function of the stomach while ensuring oncological safety. Achieving this goal relies heavily on the development and integration of two key techniques. First is Laparoscopic Sentinel Node Navigation Surgery (LSNNS). Sentinel lymph nodes are the first or group of lymph nodes along the primary tumour's lymphatic drainage pathway, and their pathological state is considered to highly predict metastasis in all lymph nodes in that region. In gastric cancer surgery, by injecting tracers (such as the fluorescent dye indocyanine green) under the mucosa around the tumour, and using the magnified view and fluorescence imaging system of laparoscopy, these sentinel lymph nodes can be located and removed in real time for intraoperative rapid pathological examination. The National Cancer Center in South Korea conducted a multicentre phase III randomised controlled clinical trial (SENORITA) on laparoscopic sentinel node navigation surgery for function-preserving surgery in early gastric cancer. In the LSNNS group, 210 patients (81%) underwent stomach-preserving surgery, and the results showed no significant difference in postoperative complication rates, 5-year local recurrence, disease-free survival (DFS), and overall survival (OS) compared to conventional laparoscopic radical gastrectomy. However, the LSNNS group had significantly better postoperative quality of life. These study results suggest that due to the complexity of gastric cancer lymphatic drainage and the skip and uncertain nature of metastasis, detecting the sentinel lymphatic basin (SLB) can provide a more comprehensive understanding of sentinel nodes, offering precise guidance for individualised lymph node dissection and avoiding unnecessary extended lymph node removal, reducing surgical trauma and related complications without compromising oncological outcomes.
Laparoscopic and endoscopic cooperative surgery (LECS) combines the advantages of laparoscopic internal view and operation with the precise localisation and removal capabilities of endoscopy. It's become a hot research topic in stomach-function-preserving surgery in recent years. Endoscopy provides a high-definition view of the mucosal surface from inside the cavity, allowing precise marking of tumour boundaries and submucosal dissection, while laparoscopy offers an external view of the serosal surface, enabling reliable full-thickness gastric wall resection, accurate suturing and regional lymph node inspection and management. Main LECS procedures include laparoscopic-assisted endoscopic full-thickness resection (LAEFR), endoscope-assisted wedge resection (EAWR), classic LECS and modified LECS. Several studies both domestic and international have shown LECS has advantages in treating various gastrointestinal tumours, but standardised procedures for early gastric cancer are not yet established, and current data is largely from retrospective studies, lacking high-quality prospective evidence.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Shandong
-
Qingdao、Shandong、中国、266000
- Qingdao University Affiliated Hospital West Coast Campus
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age 18-80, any gender;
- Gastric adenocarcinoma confirmed by gastroscopic biopsy, with a single lesion;
- Clinical staging cT1N0M0 based on enhanced CT, endoscopic ultrasound and other imaging evaluations (tumour limited to the mucosa or submucosa with no evidence of lymph node or distant metastasis);
- Absolute indications for endoscopic submucosal dissection (ESD), with lesions no larger than 5cm, or cases where endoscopic removal is difficult. Absolute indications for ESD (differentiated carcinoma, mucosal T1a stage, without ulcer ≤2 cm or with ulcer ≤3 cm; undifferentiated carcinoma without ulcer ≤2 cm. Difficult cases for endoscopic removal: negative "lifting sign", laterally spreading tumours and scar ulcers etc.);
- Meets eCURA score criteria for non-curative ESD requiring additional surgery;
- ECOG performance status 0-1;
- Patient fully informed and consents, signing the consent form. Note: For inclusion, meeting either criterion ④ or ⑤ is sufficient.
Exclusion Criteria:
- Pregnant or breastfeeding women;
- Those with a history of major upper abdominal surgery where severe abdominal adhesions are expected;
- Patients with recurrent gastric cancer, multiple primary tumours, or those who have undergone preoperative chemoradiotherapy;
- Those meeting ESD indications and having completed curative endoscopic resection according to eCURA standards [12,13];
- Patients with other unresectable malignant tumours;
- Those with severe heart, lung, liver, or kidney dysfunction who cannot tolerate general anaesthesia and surgery;
- Those allergic to indocyanine green (ICG) or nano carbon tracers;
- Those with mental illness who cannot cooperate with the study and follow-up.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Perform a combined surgery using both microscopes
|
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Postoperative complications within 30 days after surgery
大体时间:Within 30 days after surgery
|
Within 30 days after surgery
|
|
Overall survival (OS)
大体时间:1 year and 3 years after surgery
|
1 year and 3 years after surgery
|
|
disease-free survival (DFS)
大体时间:1 year and 3 years after surgery
|
1 year and 3 years after surgery
|
|
Local recurrence rate (LR)
大体时间:1 year and 3 years after surgery
|
1 year and 3 years after surgery
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Sentinel lymph node prediction accuracy (sensitivity, specificity, etc.)
大体时间:Up to two weeks after surgery (confirmed by paraffin pathology)
|
Up to two weeks after surgery (confirmed by paraffin pathology)
|
|
Sentinel lymph node tracing success rate
大体时间:At most, no more than 2 hours after receiving the specimen for frozen biopsy (intraoperative sentinel lymph node frozen pathology)
|
At most, no more than 2 hours after receiving the specimen for frozen biopsy (intraoperative sentinel lymph node frozen pathology)
|
|
R0 resection rate
大体时间:Up to two weeks after surgery(confirmed by paraffin pathology)
|
Up to two weeks after surgery(confirmed by paraffin pathology)
|
|
EORTC QLQ-C30/STO22 scale scores(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30)
大体时间:Before the surgery, and at 3, 6, 12 months after, and 2, 3 years post-surgery
|
Before the surgery, and at 3, 6, 12 months after, and 2, 3 years post-surgery
|
|
Weight and Body Mass Index
大体时间:Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after
|
Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after
|
|
Albumin and haemoglobin(g/L)
大体时间:Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after
|
Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after
|
|
NRS2002 Nutrition Risk Screening
大体时间:Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after
|
Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.